ICYMI, this week we had news about Masterclasses in Dermatology, JNJ-2113's significant PASI and IGA responses for plaque psoriasis, Almirall's partnership with the Centre for Genomic Regulation, and more.
Keep up with the latest headlines in dermatology from the past week, including the role of the US in hosting more than half of the world's skin cancer-related trials, new AAD guidelines for acne, and more.
The Technology Breakthrough designation will enable health care providers to access exclusive pricing and terms for the solution in pediatric burn care.
Investigators highlighted the importance of considering household second hand smoke exposure when evaluating adolescents with AD.
The submission deadline for this year’s awards and grants is Friday, March 15, 2024. Award recipients will be notified in June 2024, and the grant period for all awards is 1 year beginning on July 1, 2024.
The conference's course directors give a sneak peek of what in-person and virtual attendees will learn about AI, alternative medicine, surgical management of HS, and more.
This year is already off to a busy start, and Dermatology Times is prepared to provide our readers with the most up-to-date clinical content from innovative studies and FDA approvals to exclusive interviews and expert insights.
Researchers explored the efficacy of a multistep treatment strategy in a younger patient population.
The partnership and newly-established center will develop dermatological research and delve into skin aging, skin allergies, and inflammatory or eczematous conditions.
A team of dermatology physician assistants recently reviewed the current and future potential of genomic testing in the realm of dermatology.
Atopic dermatitis flares are about more than just skin symptoms and are difficult to quantify, according to a study that asked patients to describe them.
Star Trek may call space “the final frontier,” but it’s really the next exciting frontier for humans. For now, we can learn about the various new innovations and therapies for skin disease at the AAD annual meeting—and continue to strive to improve our patients’ lives here on Earth.
Decentralized clinical trials (are emerging as a crucial avenue for transforming this gender bias and fostering inclusivity within health care research.
Exposure led to an increase in total plasma IgE levels but reduced epidermal thickening, mast cell number, and plasma histamine levels in the early stages of AD.
An increased number of tubes of aminolevulinic acid hydrochloride 10% will help patients who have actinic keratosis over large surface areas.
There’s nothing worse than having OTC products fight back against the progress we make with our prescription therapies.
Data from the FRONTIER 1 clinical trial were recently published in the New England Journal of Medicine.
Krystal Biotech’s B-VEC was administered as an eyedrop for a patient with dystrophic epidermolysis bullosa with cicatrizing conjunctivitis.
For the third consecutive year, physician assistants ranked number 2 behind nurse practitioners in the individual healthcare sector listing.
The partnership is focused on exploring innovative therapeutic strategies to address AD.
Biologics represent the pinnacle of scientific progress, engineered to precisely target conditions previously deemed untreatable. However, any dermatology provider who has prescribed one quickly learns of the immense barriers surrounding them.
Dermatologists Jeanine Downie, DiAnne Davis, and Hope Mitchell reveal the La Roche-Posay products they recommend to patients with dry skin, eczema, and more, at the flagship store in France.
A discussion among roundtable participants revolved around the importance of effective communication, the impact of prolonged use of topical steroids, and the need for trust building in recommending novel treatment options.
Interim data from the clinical trial was presented in a poster at the South Beach Symposium, with itch reduction demonstrating immediacy and long-term capability.
For a patient with vitiligo who is concerned about potential flares, what might you recommend avoiding?
Both cream options were capable of reducing scores of itching, drying, burning, redness, and more.
Shanna Miranti, MPAS, PA-C, shares updates on the status of roflumilast foam 0.3% and Cabtreo available in US pharmacies.
To stay up-to-date with the latest dermatology news, sign up to receive our eNewsletters.